The global sulphonamides market size was estimated to be USD 126.7 million in 2023 and is expected to reach USD 222.7 million by 2034 with a CAGR of 5.26% during the forecast period 2024-2034. The increasing prevalence of antibiotic-resistant bacteria, development of new sulfonamide drugs, growing demand for generic drugs, increasing demand for sulfonamides in emerging markets, increasing use of sulfonamides in veterinary medicine, and development of new applications for sulfonamides, such as the treatment of cancer will drive the market growth.
Pharmaceutical firms continually develop new sulfonamide medicines with enhanced effectiveness and safety characteristics. These new medications are projected to boost growth in the sulfonamides market in the future years. For example, combining Sulfamethoxazole and Trimethoprim is a new generation of sulfonamides that is more effective against a broader spectrum of bacteria than prior sulfonamides. For instance, GSK announced a cooperation with the University of Oxford in October 2023 to research novel medicines, including sulphonamides, to battle drug-resistant bacteria.
By route of administration, the oral segment accounted for the highest revenue-grossing segment in the global sulphonamides market in 2023 owing to the increased preference for convenient and easily administered medications, driving the demand for oral formulations of sulphonamides among healthcare practitioners and patients alike. For instance, Pfizer got FDA permission in July 2023 for a new antibiotic, Zithromax (azithromycin), a kind of sulphonamide. Additionally, the topical segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising demand for localized and targeted treatment options, increased awareness about skin infections and dermatological conditions, and advancements in topical drug delivery technologies.
By application, the urinary tract infections segment accounted for the highest revenue-grossing segment in the global sulphonamides market in 2023 owing to the rising prevalence of urinary tract infections (UTIs), especially among the global population, coupled with the effectiveness of sulphonamides in treating bacterial infections commonly associated with the urinary tract. For instance, Sanofi mentioned in May 2023 that it was divesting its animal health business, which included a variety of sulphonamide medications. Additionally, the skin infections segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing incidence of skin infections, expanding patient awareness, and the continuous development of advanced sulphonamide formulations tailored for effective dermatological treatment.
By end-user, the hospital's segment accounted for the highest revenue-grossing segment in the global sulphonamides market in 2023 owing to the prevalence of severe bacterial infections necessitating inpatient care, the widespread use of sulphonamides in hospitals for treating a range of infectious diseases, and the critical role of hospitals in managing and containing outbreaks. For instance, in March 2023, Roche announced a CHF 1 billion investment in a new research and development facility in China, which would focus on the development of novel antibiotics, including sulphonamides. Additionally, the outpatient clinics segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing trend towards ambulatory care, rising emphasis on early detection and treatment of infections in outpatient settings, and the growing popularity of sulphonamides for managing a variety of bacterial ailments in a more accessible and convenient healthcare environment.
North American region is anticipated to have the highest revenue share during the forecast period owing to the robust research and development activities, a strong focus on infectious disease management, and a favorable regulatory environment, collectively contributing to the sustained demand for sulphonamides in the region. For instance, Merck stated in February 2023 that it will collaborate with the Bill & Melinda Gates Foundation to research new antibiotics, including sulphonamides, for use in low- and middle-income nations. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing incidence of infectious diseases, a rapidly expanding population, and ongoing efforts to improve healthcare accessibility.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Pharmaceutical firms continually develop new sulfonamide medicines with enhanced effectiveness and safety characteristics. These new medications are projected to boost growth in the sulfonamides market in the future years. For example, combining Sulfamethoxazole and Trimethoprim is a new generation of sulfonamides that is more effective against a broader spectrum of bacteria than prior sulfonamides. For instance, GSK announced a cooperation with the University of Oxford in October 2023 to research novel medicines, including sulphonamides, to battle drug-resistant bacteria.
By route of administration, the oral segment accounted for the highest revenue-grossing segment in the global sulphonamides market in 2023 owing to the increased preference for convenient and easily administered medications, driving the demand for oral formulations of sulphonamides among healthcare practitioners and patients alike. For instance, Pfizer got FDA permission in July 2023 for a new antibiotic, Zithromax (azithromycin), a kind of sulphonamide. Additionally, the topical segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising demand for localized and targeted treatment options, increased awareness about skin infections and dermatological conditions, and advancements in topical drug delivery technologies.
By application, the urinary tract infections segment accounted for the highest revenue-grossing segment in the global sulphonamides market in 2023 owing to the rising prevalence of urinary tract infections (UTIs), especially among the global population, coupled with the effectiveness of sulphonamides in treating bacterial infections commonly associated with the urinary tract. For instance, Sanofi mentioned in May 2023 that it was divesting its animal health business, which included a variety of sulphonamide medications. Additionally, the skin infections segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing incidence of skin infections, expanding patient awareness, and the continuous development of advanced sulphonamide formulations tailored for effective dermatological treatment.
By end-user, the hospital's segment accounted for the highest revenue-grossing segment in the global sulphonamides market in 2023 owing to the prevalence of severe bacterial infections necessitating inpatient care, the widespread use of sulphonamides in hospitals for treating a range of infectious diseases, and the critical role of hospitals in managing and containing outbreaks. For instance, in March 2023, Roche announced a CHF 1 billion investment in a new research and development facility in China, which would focus on the development of novel antibiotics, including sulphonamides. Additionally, the outpatient clinics segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing trend towards ambulatory care, rising emphasis on early detection and treatment of infections in outpatient settings, and the growing popularity of sulphonamides for managing a variety of bacterial ailments in a more accessible and convenient healthcare environment.
North American region is anticipated to have the highest revenue share during the forecast period owing to the robust research and development activities, a strong focus on infectious disease management, and a favorable regulatory environment, collectively contributing to the sustained demand for sulphonamides in the region. For instance, Merck stated in February 2023 that it will collaborate with the Bill & Melinda Gates Foundation to research new antibiotics, including sulphonamides, for use in low- and middle-income nations. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing incidence of infectious diseases, a rapidly expanding population, and ongoing efforts to improve healthcare accessibility.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Route of Administration, Application, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
Segmentation: Sulphonamides Market Report 2023 - 2034
Sulphonamides Market Analysis & Forecast by Route of Administration 2023 - 2034 (Revenue USD Mn)
- Oral
- Topical
- Others
Sulphonamides Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Mn)
- Skin Infection
- Gastro-Intestinal Tract (GIT) Infection
- Urinary Tract Infection (UTI)
- Respiratory Tract Infection (RTI)
- Other
Sulphonamides Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Mn)
- Hospitals
- Clinics
- Long-Term Care Facilities
- Veterinary Clinics
Sulphonamides Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Mn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Sulphonamides Market: Route of AdministrationEstimates & Trend Analysis
8. Sulphonamides Market: Application Estimates & Trend Analysis
9. Sulphonamides Market: Distribution Channel Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Sulphonamides Market
12. Europe Global Sulphonamides Market
13. Asia Pacific Global Sulphonamides Market
14. Latin America Global Sulphonamides Market
15. MEA Global Sulphonamides Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- GlaxoSmithKline plc
- Pfizer Inc.
- Sanofi S.A.
- Roche Holding AG
- Merck & Co. Inc.
- Novartis AG
- Bayer AG
- Johnson & Johnson
- Abbott Laboratories
- Bristol Myers Squibb Company
- Eli Lilly and Company
- AstraZeneca plc
- Boehringer Ingelheim International GmbH
- Teva Pharmaceutical Industries Ltd.
- Sun Pharmaceutical Industries Ltd
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | January 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 126.7 Million |
| Forecasted Market Value ( USD | $ 222.7 Million |
| Compound Annual Growth Rate | 5.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
